Multimodal Treatment of Nasopharyngeal Carcinoma in Children, Adolescents and Young Adults-Extended Follow-Up of the NPC-2003-GPOH Study Cohort and Patients of the Interim Cohort

T. Roemer, S. Franzen, H. Kravets, A. Farrag, A. Makowska, H. Christiansen, M.J. Eble, B. Timmermann, G. Staatz, F.M. Mottaghy, M. Buehrlen, U. Hagenah, A. Puzik, P.H. Driever, J. Greiner, N. Jorch, S. Tippelt, D.T. Schneider, G. Kropshofer, T.R. OverbeckT. Brozou, G. Escherich, M. Becker, W. Friesenbichler, T. Feuchtinger, W. Puppe, N. Heussen, R.D. Hilgers, U. Kontny*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Simple Summary Multimodal treatment of nasopharyngeal carcinoma (NPC) in children and young adults with induction chemotherapy, followed by radiochemotherapy and interferon-beta (IFN-beta) maintenance, has been successfully applied in studies NPC-91 and NPC-2003 of the German Society of Pediatric Oncology and Hematology (GPOH). We, here, present updated survival rates of the NPC-2003 study cohort after longer follow-up and include 21 additional patients recruited after closure of the study and treated as per the NPC-2003 study protocol (interim cohort) in our survival analysis. Survival rates remain high after extended follow-up and in the larger cohort with EFS and OS of 94% and 97%, respectively, reinforcing the high antitumor efficacy of this multimodal treatment concept. Seven patients with CR after induction therapy received a reduced radiation dose of 54 Gy, and none of them relapsed. Thus, the reduction of radiation dose seems feasible and has the potential to reduce treatment-related late effects in this vulnerable population. Nasopharyngeal carcinoma (NPC) in children and young adults has been treated within two consecutive prospective trials in Germany, the NPC-91 and the NPC-2003 study of the German Society of Pediatric Oncology and Hematology (GPOH). In these studies, multimodal treatment with induction chemotherapy, followed by radio (chemo)therapy and interferon-beta maintenance, yielded promising survival rates even after adapting total radiation doses to tumor response. The outcome of 45 patients in the NPC-2003 study was reassessed after a median follow-up of 85 months. In addition, we analyzed 21 further patients after closure of the NPC-2003 study, recruited between 2011 and 2017, and treated as per the NPC-2003 study protocol. The EFS and OS of 66 patients with locoregionally advanced NPC were 93.6% and 96.7%, respectively, after a median follow-up of 73 months. Seven patients with CR after induction therapy received a reduced radiation dose of 54 Gy; none relapsed. In young patients with advanced locoregional NPC, excellent long-term survival rates can be achieved by multimodal treatment, including interferon-beta. Radiation doses may be reduced in patients with complete remission after induction chemotherapy and may limit radiogenic late effects.
Original languageEnglish
Article number1261
Number of pages17
JournalCancers
Volume14
Issue number5
DOIs
Publication statusPublished - 1 Mar 2022

Keywords

  • nasopharyngeal carcinoma
  • platin-based chemotherapy
  • radiotherapy
  • interferon-beta
  • late toxicities
  • children
  • adolescents
  • young adults
  • INTENSITY-MODULATED RADIOTHERAPY
  • INTERFERON-BETA
  • MULTIPLE-SCLEROSIS
  • ADJUVANT CHEMOTHERAPY
  • ANTITUMOR-ACTIVITY
  • DEPRESSION
  • PHASE-2
  • 5-FLUOROURACIL
  • PEMBROLIZUMAB
  • TOLERABILITY

Cite this